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To the Editor:
We read with interest the study by
Hecht-Dolnik and associates in the Sep-
tember 2009 issue of the Journal, ‘‘He-
tastarch Increases the Risk of Bleeding
Complications in Patients After Off-
Pump Coronary Bypass Surgery: A
Randomized Clinical Trial.’’ In this ar-
ticle, they conclude that the intraopera-
tive administration of 1 L of hetastarch
was associated with an increase in post-
operative chest tube drainage and trans-
fusion of blood products, which resulted
in early termination of the study.
Although we acknowledge the im-
portance of the clinical question the au-
thors have addressed, we have major
concerns regarding the equality of the
intervention and the control groups at
baseline and the method in which this
is reported. Although the authors claim
that there were no statistically signifi-
cant differences in baseline character-
istics between groups, Table 1
indicates the baseline international nor-
malized ratio (INR) in the hetastarch
group was 1.47 (2.12) whereas in the
albumin group baseline INR was 1.07
(0.10), values presented as mean (stan-
dard deviation). Although the mean
value between these 2 groups may not
be statistically different, it is mislead-
ing to claim baseline equivalence be-
tween the groups. The upper limit of
INR is typically quoted at 1.3, indicat-
ing the mean INR in the hetastarch
group is abnormal and in the albumin
group mean INR is normal. Further-
more, the large standard deviation in
baseline INR in the hetastarch group
can only be explained by the presence
of one or more outliers with markedly
abnormal baseline value. In contrast,
the standard deviation for INR of theThe Journalalbumin group is small (0.10), indicat-
ing a typically normal distribution. We
would suggest that this method of re-
porting baseline INR is potentially mis-
leading. Presenting the proportion of
patients in each group with abnormal
INR at baseline would be substantially
more informative to judge baseline
equivalence of the 2 groups.
This difference in baseline INR and,
by inference, bleeding risk is difficult to
explain in a trial whose group assign-
ment was by random allocation. How-
ever, in a study whose primary
outcome was transfusion of blood prod-
ucts, understanding a difference of this
nature is vitally important to interpreta-
tion of the results, particularly where
transfusion practice was neither blinded
nor protocol guided, as in this study.
We believe this highlights the im-
portance of using the appropriate
method of data presentation to describe
baseline characteristics in a clinical
trial as well as the potential pitfall of re-
lying on P values greater than .05 to in-
dicate baseline equivalence of groups
rather than clinical interpretation for
the potential influence of an observed
difference on the outcome of interest.
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Ervant Nishanian, MD, PhD
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doi:10.1016/j.jtcvs.2009.10.058Reply to the Editor:
We extend our thanks to Drs McIlroy
and Nishanian for their careful reading
of our article. Their concerns would
be well placed if the average baseline
international normalized ratio (INR) in
the hetastarch group were 1.47. Their
comment led us to review the project
source data. That review revealed
several transcription errors in which
the decimal place in the INR was mis-
placed. The average baseline INR after
correction of those transcription errorsof Thoracic and Cardiovascular Surgeis 1.06 (standard deviation ¼ 0.11).
This correction thus reverses the direc-
tion of the difference between the
hetastarch and albumin groups in the
average INR from that presented in
the initial article. The statistical signifi-
cance of the difference in average INR
between the albumin and hetastarch
groups becomes even weaker, remain-
ing not statistically significant (Student
t ¼ 0.77; P ¼ .44, not significant).
We then investigated how many
cases in each group had a baseline
INR above the 1.30 threshold, as Drs
McIlroy and Nishanian suggested.
That threshold is crossed by 2 members
(2.6%) of the albumin group and 3
members (3.8%) of the hetastarch
group. The difference in the proportion
in each group with an INR above the 1.3
threshold is not statistically significant
(Fisher exact test¼ 1.0, not significant).
This corrected finding supports
treating the intervention and control
groups in this study as equivalent. We
apologize for any misunderstandings
caused by this inaccuracy in the initial
reported statistics summarizing and
comparing baseline characteristics.
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THE TREATMENT OF
ANOMALOUS ORIGINS OF
RIGHT OR LEFT
CORONARYARTERIES
ASSOCIATED WITH
AORTOPULMONARY
WINDOWS
To the Editor:
Aortopulmonary window (APW)
and anomalous right coronary artery
(RCA) originating from the pulmonaryry c Volume 139, Number 3 801
